OCM was defined as death from other causes. Competing-risk analyses generated cumulative-incidence CSM and OCM rates according to PSM and their characteristics. The same analyses were repeated after stratifying patients in two groups: favorable (pT2 and pathologic grade group 1-3 and pN0/x) vs. adverse pathologic characteristics (pT3b/4 and/or pathologic grade group 4-5 and/or pN1). Multivariable competing-risks regression models assessed the effect of PSM on CSM after accounting for OCM.
INTRODUCTION AND OBJECTIVES: Studies on adverse effects of different androgen deprivation therapies (ADT) have previously focused on specific conditions (coronary heart disease, stroke, diabetes, fractures). None have reported effects on overall comorbidity. The objective of this study was to compare the increase in overall comorbidity among men receiving gonadotrophin releasing (GnRH) agonists with those on anti-androgen (AA) monotherapy (predominantly 150 mg bicalutamide daily) for advanced prostate cancer (PCa).
METHODS: Men on either GnRH (n[4887) or AA (n[2078) for high risk or regionally advanced PCa were selected from the Swedish Prostate Cancer Database PCBaSE 3.0, along with agematched PCa-free men for comparison. Incremental change in comorbidity was assessed in all study participants using the Charlson Comorbidity Index (CCI), calculated from 5yrs before through to 5yrs after the ADT start date. The difference in excess rate of CCI increase for men on GnRH agonists compared with men on AA monotherapy was determined using multivariable linear regression, with separate models for periods before and after starting ADT. The difference in risk of any new additional comorbidity after starting ADT was assessed using multivariable Cox proportional hazards regression.
RESULTS: The difference in excess rate of change in CCI after starting ADT was greater for men on GnRH agonists than AA monotherapy (5.7% per year; 95%CI 2.9 to 8.5% per year). No difference was evident before starting ADT. Risk of any new comorbidity following the start of ADT was also increased in men on GnRH agonists compared with AA monotherapy (HR: 1.32; 95% CI:1.20-1.44).
CONCLUSIONS: These findings suggest that the rate of increase in overall comorbidity is greater among men on GnRH agonists than men on AA monotherapy, irrespective of baseline comorbidity. Due to limitations inherent in observational studies, these results should be confirmed through randomized controlled trials to better inform treatment decisions for PCa when curative therapies are not an option. RESULTS: Overall 55 patients received aADT, 34 aADT þ aRT and 184 observation (including 96 with salvage ADT). For the entire cohort 2-year BCR-free survival, MP-free survival and overall survival rates were 33.0% (27.2-40.1%), 76.6% (71.0-82.8%) and 90.3% (86.1-94.8%). While patients with aADT þ aRT had significantly better BCR-free survival rates (78.6% vs. 29.7% (aADT) vs. 25.8% (observation), p<0.001) MP-free survival and overall survival did not differ between the groups (p>0.05). In multivariable Cox regression analyses aADTþaRT was significantly associated with a lower BCR rate (HR aADT: 5.55, HR observation: 6.15, both p<0.001), while there was no effect on MP or overall mortality (p>0.05).
CONCLUSIONS: In patients with high lymph node burden, combination of aADTþaRT might lower BCR risk. However, further oncological outcomes, namely MP and overall mortality, were not affected by the addition of radiation therapy.
Source of Funding: none

MP22-13 IMPACT OF RELATIONAL COHESION AND SEXUALITY ON THE QUALITY OF LIFE OF PATIENTS TREATED WITH GONADOTROPIN-RELEASING HORMONE (GNRH) AGONIST FOR PROSTATE CANCER: FINAL ANALYSIS OF THE EQUINOXE STUDY
St ephane Droupy*, Nîmes, France; Marie-H el ene Colson, Marseille, France; Nathalie Pello-Leprince-Ringuet, Val erie Perrot, Boulogne-Billancourt, France; Aurelien Descazeaud, Limoges, France INTRODUCTION AND OBJECTIVES: The first few months of treatment for prostate cancer (PCa) are a difficult time for a couple. The degree of relational cohesion could have an effect on the experience of the disease. We analyzed the factors influencing the evolution of quality of life (QoL) in patients with PCa treated with hormone therapy for 6 months.
METHODS: French prospective, multicenter, longitudinal and non-interventional study (NCT02630641). Urologists recruited partnerpatient couples with PCa for whom hormone therapy was indicated. Data were collected at inclusion and after 6 months of treatment, on Vol. 201, No. 4S, Supplement, Saturday, May 4, 2019 THE JOURNAL OF UROLOGY Ò e321
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